# A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

> **NCT04700449** · PHASE2 · COMPLETED · sponsor: **Connect Biopharm LLC** · enrollment: 145 (actual)

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

- **DRUG:** Double-Blind 0.2mg CBP-307
- **DRUG:** Double-Blind Placebo
- **DRUG:** Open-label CBP-307
- **DRUG:** Double-Blind 0.1mg CBP-307

## Key facts

- **NCT ID:** NCT04700449
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-27
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-11-10
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700449, "A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04700449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*